Mirum Pharmaceuticals Inc
MIRM74.380USD
-0.940-1.25%
收盘 09/19, 16:00（美东）报价延迟15分钟
3.72B总市值
亏损市盈率 TTM
关于 Mirum Pharmaceuticals Inc 公司
Mirum Pharmaceuticals, Inc. 是一家生物制药公司。该公司专注于识别、收购、开发和商业化治疗衰弱性罕见病和孤儿病的疗法。该公司有三种药物：LIVMARLI（maralixibat）口服溶液（Livmarli）、Cholbam（胆酸）胶囊和 Chenodal（chenodiol）片剂。Livmarli 是一种口服、最低吸收的回肠胆汁酸转运蛋白 (IBAT) 抑制剂 (IBATi)，用于治疗美国和其他多个国家 Alagille 综合征 (ALGS) 患者的胆汁淤积性瘙痒以及美国进行性家族性肝内胆汁淤积 (PFIC) 患者的胆汁淤积性瘙痒。Cholbam 用于治疗因单一酶缺乏引起的胆汁酸合成障碍和过氧化物酶体疾病的辅助治疗。该公司还在推进其候选产品 volixibat，用于治疗患有胆汁淤积性肝病的成年患者。
公司简介
公司代码MIRM
公司名称Mirum Pharmaceuticals Inc
上市日期Jul 18, 2019
CEOMr. Christopher (Chris) Peetz
员工数量322
证券类型Ordinary Share
年结日Jul 18
公司地址989 East Hillsdale Boulevard, Suite 300
城市FOSTER CITY
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编94404
电话16506674085
网址https://mirumpharma.com/
公司代码MIRM
上市日期Jul 18, 2019
CEOMr. Christopher (Chris) Peetz
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
39.66K
+28.33%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
5.65K
--
Mr. Andrew Mckibben
Mr. Andrew Mckibben
Investor Relations
Investor Relations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
39.66K
+28.33%
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
业务USD
名称
营收
占比
Livmarli
73.22M
65.62%
Bile Acid Medicines
38.36M
34.38%
License and other revenue
0.00
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
Livmarli
73.22M
65.62%
Bile Acid Medicines
38.36M
34.38%
License and other revenue
0.00
0.00%
股东统计
更新时间: 8月24日 周日
更新时间: 8月24日 周日
持股股东
股东类型
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
13.53%
Janus Henderson Investors
10.42%
BlackRock Institutional Trust Company, N.A.
6.18%
BVF Partners L.P.
5.50%
Eventide Asset Management, LLC
5.25%
其他
59.12%
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
13.53%
Janus Henderson Investors
10.42%
BlackRock Institutional Trust Company, N.A.
6.18%
BVF Partners L.P.
5.50%
Eventide Asset Management, LLC
5.25%
其他
59.12%
股东类型
持股股东
占比
Investment Advisor
34.65%
Investment Advisor/Hedge Fund
33.04%
Hedge Fund
22.05%
Private Equity
14.00%
Research Firm
4.35%
Venture Capital
2.99%
Individual Investor
1.88%
Sovereign Wealth Fund
1.01%
Pension Fund
0.69%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
458
58.36M
116.21%
-4.59M
2025Q1
454
57.59M
116.38%
-4.84M
2024Q4
425
56.60M
115.52%
-10.44M
2024Q3
408
56.58M
118.52%
-12.05M
2024Q2
398
57.22M
121.33%
-10.51M
2024Q1
391
57.27M
121.82%
-5.03M
2023Q4
376
54.05M
116.10%
-4.66M
2023Q3
337
55.34M
123.03%
+4.03M
2023Q2
315
43.67M
117.43%
-6.40M
2023Q1
289
41.51M
112.21%
-7.06M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
6.80M
13.72%
+3.07M
+82.21%
Mar 31, 2025
Janus Henderson Investors
5.08M
10.26%
+83.18K
+1.66%
May 30, 2025
BlackRock Institutional Trust Company, N.A.
3.02M
6.09%
-81.87K
-2.64%
Mar 31, 2025
BVF Partners L.P.
2.80M
5.65%
--
--
Mar 31, 2025
Eventide Asset Management, LLC
2.53M
5.1%
-79.94K
-3.07%
Mar 31, 2025
The Vanguard Group, Inc.
2.53M
5.11%
+115.33K
+4.77%
Mar 31, 2025
Novo Holdings A/S
1.50M
3.03%
--
--
Mar 31, 2025
Citadel Advisors LLC
1.45M
2.92%
-65.19K
-4.31%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.38M
2.79%
-8.29K
-0.60%
Mar 31, 2025
State Street Global Advisors (US)
1.49M
3.02%
+112.94K
+8.17%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
F/m Emerald Life Sciences Innovation ETF
2.74%
Invesco Dorsey Wright Healthcare Momentum ETF
1.93%
ALPS Medical Breakthroughs ETF
1.59%
First Trust Small Cap Growth AlphaDEX Fund
0.95%
SPDR S&P Biotech ETF
0.7%
First Trust Small Cap Core Alphadex Fund
0.45%
Direxion Daily S&P Biotech Bull 3X Shares
0.4%
iShares Biotechnology ETF
0.28%
iShares Russell 2000 Growth ETF
0.21%
Principal U.S. Small-Cap ETF
0.2%
查看更多
F/m Emerald Life Sciences Innovation ETF
占比2.74%
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.93%
ALPS Medical Breakthroughs ETF
占比1.59%
First Trust Small Cap Growth AlphaDEX Fund
占比0.95%
SPDR S&P Biotech ETF
占比0.7%
First Trust Small Cap Core Alphadex Fund
占比0.45%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.4%
iShares Biotechnology ETF
占比0.28%
iShares Russell 2000 Growth ETF
占比0.21%
Principal U.S. Small-Cap ETF
占比0.2%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
